Skip to content
Open access

Impact of Carboplatin on Long-Term Survival after Neoadjuvant Chemotherapy in Non-Metastatic Triple-Negative Breast Cancer: An Algerian Cohort Study

Oct 2026 · Archives of Breast Cancer · 0 citations · 27 references

Abstract

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression. Platinum agents such as carboplatin have been incorporated into neoadjuvant regimens to improve pathological complete response (pCR), but their long-term survival benefit remains unclear, particularly in North African populations.Methods: We conducted a retrospective cohort study with prospective longitudinal follow-up of 183 Algerian women with nonmetastatic TNBC who received neoadjuvant chemotherapy between February 2015 and February 2017 at the Pierre and Marie Curie Cancer Center, Algiers. Patients received six cycles of docetaxel plus anthracycline–cyclophosphamide (FAC60), with or without the addition of carboplatin (AUC 5). After surgery, patients were followed for overall survival (OS) and event-free survival (EFS) until November 2024. Statistical analyses were performed using R version 4.3.2.Results: The median age was 43 years; 74% were premenopausal. The pCR rate was significantly higher with the carboplatin-containing regimen than without carboplatin (58% vs 36%, P = .004). After a median follow-up of 103 months (range, 9-118 months), 3-, 5-, and 8-year OS rates in the carboplatin group were 89%, 83.5%, and 75.2%, respectively. However, the carboplatin-containing regimen did not improve OS (P = .34) or EFS (P = .49). Achieving pCR was independently associated with better survival outcomes (EFS P < .001 and OS P < .001, respectively) in multivariable Cox regression models.Conclusion: Among Algerian women with nonmetastatic TNBC, the carboplatin-containing regimen increased pCR rates but did not improve long-term survival. Pathologic complete response was an independent predictor of favorable prognosis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.